Sexual dysfunctions (SD) and selective serotonin reuptake inhibitors (SSRIs): from preclinical studies to intervention strategies


Creative Commons License

Kaloğlu H. A., Öztürk G. S., Dilekoz E.

Anatolian Current Medical Journal, cilt.6, sa.5, ss.341-348, 2024 (Hakemli Dergi) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 6 Sayı: 5
  • Basım Tarihi: 2024
  • Doi Numarası: 10.38053/acmj.1536739
  • Dergi Adı: Anatolian Current Medical Journal
  • Derginin Tarandığı İndeksler: TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.341-348
  • Gazi Üniversitesi Adresli: Evet

Özet

In the light of existing literature, we reviewed the causes, management and potential therapeutic benefits of SSRI (Selective serotonin reuptake inhibitor) agents regarding sexual functions. (SSRIs) are the most commonly used medications for the treatment of depression, based on their effectiveness and safety profile. Sexual dysfunctions (SD) caused by SSRIs are one of the most important reasons for discontinuation of treatment in both genders. Knowing the intervention strategies in patients who develop SD is pivotal for the proper management of sexual side effects and the treatment adherence of patients. The effects of SSRIs on sexual functions can also be used to treat certain disorders. SSRIs have a high success rate in the treatment of premature ejaculation and their off-label use for this purpose is widely recognized.